IL-4 within the bone marrow: a key driver of lung tumorigenesis

Yoshimasa Tanaka

DOI: https://doi.org/10.1093/jleuko/qiae033

2024-03-12

Journal of Leukocyte Biology

Abstract:Interleukin-4 in bone marrow serves as a driver of lung cancer. Combining interleukin-4 receptor α chain blockade with immune checkpoint inhibitors has the potential for a novel superior cancer immunotherapy targeting the tumor microenvironment.

immunology,cell biology,hematology

What problem does this paper attempt to address?

Endogenously Expressed IL-4Rα Promotes the Malignant Phenotype of Human Pancreatic Cancer in Vitro and in Vivo

Benno Traub,Lie Sun,Yongsu Ma,Pengfei Xu,Johannes Lemke,Stephan Paschke,Doris Henne-Bruns,Uwe Knippschild,Marko Kornmann

DOI: https://doi.org/10.3390/ijms18040716

IF: 5.6

2017-01-01

International Journal of Molecular Sciences

Abstract:Exogenous interleukin-4 (IL-4) has been demonstrated to affect the growth of different human malignancies including pancreatic cancer cells. The aim of our study was to determine the role of endogenously expressed IL-4-receptor-α-chain (IL-4Rα) in pancreatic cancer cells. IL-4Rα-suppression was achieved by generating Capan-1 cells stably expressing shRNA targeting IL-4Rα. The malignant phenotype was characterized by assessing growth properties, directional and non-directional cell movement in vitro and tumor growth in vivo. Signaling pathways were analyzed upon IL-4 and IL-13 stimulation of wildtype (WT) and control-transfected cells compared to IL-4Rα-knockdown cells. Silencing of IL-4Rα resulted in reduced anchorage-dependent cell growth (p < 0.05) and reduced anchorage-independent colony size (p < 0.001) in vitro. Moreover, cell movement and migration was inhibited. IL-4 and IL-13 stimulation of Capan-1-WT cells induced activation of similar pathways like stimulation with Insulin-like growth factor (IGF)-I. This activation was reduced after IL-4Rα downregulation while IGF-I signaling seemed to be enhanced in knockdown-clones. Importantly, IL-4Rα silencing also significantly suppressed tumor growth in vivo. The present study indicates that endogenously expressed IL-4 and IL-4Rα contribute to the malignant phenotype of pancreatic cancer cells by activating diverse pro-oncogenic signaling pathways. Addressing these pathways may contribute to the treatment of the disease.
IL4I1: a novel molecular biomarker represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer

Xiangrong Peng,Chuan Liu,Li Zhang,Yin Chen,Lixin Mao,Shenglin Gao,Xiaokai Shi,Li Zuo

DOI: https://doi.org/10.3389/fphar.2024.1365683

2024-05-30

Abstract:Introduction: IL4I1, also known as Interleukin-4-induced gene 1, is an enzyme that can modulate the immune system by acting as a L-amino acid oxidase. Nevertheless, a precise understanding of the correlation of IL4I1 with immunological features and immunotherapy efficacy in bladder cancer (BLCA) remains incomplete. Methods: We analyzed RNA sequencing data from the Cancer Genome Atlas (TCGA) to investigate the immune function and prognostic importance of IL4I1 across different cancer types. We further examined the TCGA-BLCA cohort for correlations between IL4I1 and various immunological characteristics of tumor microenvironment (TME), such as cancer immune cycle, immune cell infiltration, immune checkpoint expression and T cell inflamed score. Validation was conducted using two independent cohort, GSE48075 and E-MTAB-4321. Finally, RNA sequencing data from the IMvigor210 cohort and immunohistochemistry assays were employed to validate the predictive value of IL4I1 for the TME and immunotherapy efficacy. Results: In our findings, a positive correlation was observed between IL4I1 expression and immunomodulators expression, immune cell infiltration, the cancer immune cycle, and T cell inflamed score in BLCA, suggesting a significant link to the inflamed TME. In addition, studies have shown that IL4I1 elevated levels of individuals tend to be more performance for basal subtype and exhibit enhanced response rates to diverse treatment modalities, specifically immunotherapy. Clinical data from the IMvigor 210 cohort confirmed a higher rate of response to immunotherapy and better survival benefits in patients with high IL4I1 expression. Discussion: To summarize, our research showed that elevated IL4I1 levels are indicative of an inflamed TME, the basal subtype, and a more favorable response to various treatment methods, especially immune checkpoint blockade therapy in BLCA.
IL-20RB Mediates Tumoral Response to Osteoclastic Niches and Promotes Bone Metastasis of Lung Cancer

Yunfei He,Wenqian Luo,Yingjie Liu,Yuan Wang,Chengxin Ma,Qiuyao Wu,Pu Tian,Dasa He,Zhenchang Jia,Xianzhe Lv,Yu-Shui Ma,Haitang Yang,Ke Xu,Xue Zhang,Yansen Xiao,Peiyuan Zhang,Yajun Liang,Da Fu,Feng Yao,Guohong Hu

DOI: https://doi.org/10.1172/jci157917

IF: 19.456

2022-01-01

Journal of Clinical Investigation

Abstract:Bone is a common site of metastasis in lung cancer, but the regulatory mechanism remains incompletely understood. Osteoclasts are known to play crucial roles in osteolytic bone metastasis by digesting bone matrix and indirectly enhancing tumor colonization. In this study, we found that IL receptor 20 subunit β (IL-20RB) mediated a direct tumoral response to osteoclasts. Tumoral expression of IL-20RB was associated with bone metastasis of lung cancer, and functionally, IL-20RB promoted metastatic growth of lung cancer cells in bone. Mechanistically, tumor cells induced osteoclasts to secrete the IL-20RB ligand IL-19, and IL-19 stimulated IL-20RB–expressing tumor cells to activate downstream JAK1/STAT3 signaling, leading to enhanced proliferation of tumor cells in bone. Importantly, blocking IL-20RB with a neutralizing antibody significantly suppressed bone metastasis of lung cancer. Overall, our data revealed a direct protumor role of osteoclastic niche in bone metastasis and supported IL-20RB–targeting approaches for metastasis treatment.
IL-4 promotes immunotherapy resistance

Paula Jauregui

DOI: https://doi.org/10.1038/s41590-024-02032-3

IF: 30.5

2024-11-28

Nature Immunology

Abstract:Ovarian cancer has high clonal heterogeneity and an immunosuppressed tumor microenvironment (TME) that contribute to resistance to immunotherapy. Research now published in Cell finds that IL-4 produced by cancer cells promotes resistance to immune checkpoint blockade (ICB). To identify extracellular factors that influence ICB resistance and ovarian tumor growth, the authors assessed the impact of specific receptors and ligands involved in cancer–macrophage interactions using a spatial functional genomics approach called Perturb-map. They constructed a Pro-Code/CRISPR library targeting the selected genes, each encoding a unique protein barcode, and introduced the library into mouse ovarian cancer cells and implant them into immunocompetent mice. Cancer-derived extracellular factors such as MIF, CCL3, CCL7 and PLAUR were shown to influence tumor growth. To identify genes involved in the poor ICB response, the authors treated the mice with anti-PD1 after injection of their generated tumor cells. They found that cancer cell-derived IL-4 influences tumor sensitivity to ICB by promoting the formation of an immunosuppressive TME via its effects on tumor macrophages. These findings offer a potential therapeutic treatment for ICB-resistant tumors. Original reference: Cell https://doi.org/10.1016/j.cell.2024.10.006 (2024)

immunology
Innate lymphoid-macrophage crosstalk promotes lung cancer regression in response to IL-12 therapy

J. Henry

2019-11-28

Abstract:The ability of IL-12 to affect both innate and adaptive immunity positions this cytokine as a promising candidate to overcome the immunosuppressive microenvironment within tumours. Despite its potent activity in experimental models, the clinical use of IL 12 has been thwarted by its reported toxicity in human trials. Intranasal administration of an IL-12-coding lentivirus efficiently transduced alveolar macrophages in tumour-bearing mice, restricting IL-12 expression to the lung parenchyma and promoting rejection of established lung metastases. IL-12 stimulated IFNγ production by innate lymphoid cells (ILC), inducing the activation of interstitial macrophages, whose presence was essential for tumour eradication. These data demonstrates the potent anti tumour activity of local lentiviral IL-12 therapy against metastatic disease in the lung and the critical role played by the innate crosstalk established between ILCs and tissue resident phagocytes within the lung microenvironment.

Biology,Medicine
IL-4 Downregulates PD-L1 Level Via SOCS1 Upregulation-Induced JNK Deactivation to Enhance Antitumor Immunity in In Vitro Colorectal Cancer

Ruiyan Huang,Baofan Zhang,Wanchun Ye,Zhongjie Tang,Qingsong Zheng

DOI: https://doi.org/10.1089/jir.2024.0110

2024-10-04

Abstract:Interleukin-4 (IL-4) controls cell growth and immune system regulation in tumorigenesis and can inhibit the growth of colon cancer cell lines, but the possible mechanism is unclear. In this study, we investigated the possible mechanism of IL-4 in colorectal cancer (CRC) through in vitro experiments. CRC cells received treatment with IL-4 (50 ng/mL), investigating the suppressor of cytokine signaling 1 (SOCS1)-related mechanism underlying the role of IL-4 in the progression and immunosuppression of CRC. The malignant processes of CRC cells and CD8+T cell-mediated immune response in CRC cells were determined by CCK-8, Transwell, wound healing, and flow cytometry assays. Programmed death ligand 1 (PD-L1), SOCS1 expressions, and c-Jun N-terminal kinase (JNK) activation in CRC cells were analyzed by quantitative reverse transcription polymerase chain reaction and/or Western blot. IL-4 repressed the malignant processes, yet promoted the apoptosis of CRC cells. Besides, IL-4 downregulated PD-L1 level, upregulated SOCS1 level, and restrained JNK activation in CRC cells, while enhancing CRC cell-killing effect of CD8+T cells. IL-4-induced effects on the aforementioned malignant processes of CRC cells and the killing effect of CD8+T cells toward CRC cells were all reversed when SOCS1 was knocked down in the CRC cells. IL-4 downregulates PD-L1 level via SOCS1 upregulation-induced JNK deactivation to enhance antitumor immunity in in vitro CRC. The study provides a theoretical basis for the clinical application of IL-4 in antitumor immunity in CRC.
IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma

Jiefei Zhu,Yan Li,Xu Lv

DOI: https://doi.org/10.1007/s00251-022-01275-4

2022-09-04

Immunogenetics

Abstract:Lung adenocarcinoma (LUAD) is the major type of lung cancer and is one of the deadliest cancers worldwide. IL4I1, as a gene associated with unsatisfactory prognosis, is involved in tumor immune escape, but its immune regulatory mechanism in LUAD is limited. Bioinformatics analysis was applied to analyze the differentially expressed mRNAs and enriched signaling pathways in LUAD tissue. Quantitative real-time polymerase chain reaction (qRT-PCR) was manipulated to test IL4I1 expression. We carried out several methods to examine cell functions: CCK-8 to measure LUAD cell proliferation; flow cytometry to determine cell apoptosis; Western blot to assess the expression of JAK/STAT pathway-related proteins and PD-L1; T cell cytotoxicity assay to evaluate the effect of IL4I1 on the immune escape of LUAD cells. Through bioinformatics analysis, IL4I1 was verified to be highly expressed in LUAD tissue, participate in the modulation of JAK/STAT signaling pathway, and be positively associated with CD274 (PD-L1) expression. Cell function experiments indicated that silencing IL4I1 notably repressed LUAD cell proliferation and induced apoptosis. IL4I1 silence would block JAK/STAT signaling pathway, but this effect could be reversed by RO8191 activator treatment. Moreover, IL4I1 silence suppressed PD-L1 expression and facilitated T cell cytotoxicity, while its inhibitory impact on PD-L1 expression and immune escape of LUAD cells could be reversed by atezolizumab treatment. Overall, we confirmed that IL4I1 promoted the malignant cell behaviors and immune escape of LUAD through JAK/STAT signaling pathway. IL4I1 has the potential to be a diagnostic biomarker for LUAD.

genetics & heredity,immunology
Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies

Shan Muhammad,Tao Fan,Yang Hai,Yibo Gao,Jie He

DOI: https://doi.org/10.1186/s12943-023-01826-7

IF: 37.3

2023-07-30

Molecular Cancer

Abstract:Interleukin-2 (IL-2) and its receptor (IL-2R) are essential in orchestrating immune responses. Their function and expression in the tumor microenvironment make them attractive targets for immunotherapy, leading to the development of IL-2/IL-2R-targeted therapeutic strategies. However, the dynamic interplay between IL-2/IL-2R and various immune cells and their dual roles in promoting immune activation and tolerance presents a complex landscape for clinical exploitation. This review discusses the pivotal roles of IL-2 and IL-2R in tumorigenesis, shedding light on their potential as diagnostic and prognostic markers and their therapeutic manipulation in cancer. It underlines the necessity to balance the anti-tumor activity with regulatory T-cell expansion and evaluates strategies such as dose optimization and selective targeting for enhanced therapeutic effectiveness. The article explores recent advancements in the field, including developing genetically engineered IL-2 variants, combining IL-2/IL-2R-targeted therapies with other cancer treatments, and the potential benefits of a multidimensional approach integrating molecular profiling, immunological analyses, and clinical data. The review concludes that a deeper understanding of IL-2/IL-2R interactions within the tumor microenvironment is crucial for realizing the full potential of IL-2-based therapies, heralding the promise of improved outcomes for cancer patients.

oncology,biochemistry & molecular biology
IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy

Feng Ye,Lichong Wang,Yuanyou Li,Chengyuan Dong,Liangxue Zhou,Jianguo Xu

DOI: https://doi.org/10.3389/fimmu.2023.1338244

IF: 7.3

2024-01-06

Frontiers in Immunology

Abstract:Background: Glioma is the prevailing malignant intracranial tumor, characterized by an abundance of macrophages. Specifically, the infiltrating macrophages often display the M2 subtype and are known as tumor-associated macrophages (TAMs). They have a critical role in promoting the oncogenic properties of tumor cells. Interleukin-4-induced-1 (IL4I1) functions as an L-phenylalanine oxidase, playing a key part in regulating immune responses and the progression of various tumors. However, there is limited understanding of the IL4I1-mediated cross-talk function between TAMs and glioma cell in the glioma microenvironment. Methods: TCGA, GTEx, and HPA databases were applied to assess the IL4I1 expression, clinical characteristics, and prognostic value of pan-cancer. The link between IL4I1 levels and the prognosis, methylation, and immune checkpoints (ICs) in gliomas were explored through Kaplan–Meier curve, Cox regression, and Spearman correlation analyses. The IL4I1 levels and their distribution were investigated by single-cell analysis and the TIMER 2 database. Additionally, validation of IL4I1 expression was performed by WB, RT-qPCR, IHC, and IF. Co-culture models between glioma cells and M2-like macrophages were used to explore the IL4I1-mediated effects on tumor growth, invasion, and migration of glioma cells. Moreover, the function of IL4I1 on macrophage polarization was evaluated by ELISA, RT-qPCR, WB, and siRNA transfection. Results: Both transcriptome and protein levels of IL4I1 were increased obviously in various tumor types, and correlated with a dismal prognosis. Specifically, IL4I1 was implicated in aggressive progression and a dismal prognosis for patients with glioma. A negative association was noticed between the glioma grade and DNA promoter methylation of IL4I1. Enrichment analyses in glioma patients suggested that IL4I1 was linked to cytokine and immune responses, and was positively correlated with ICs. Single-cell analysis, molecular experiments, and in vitro assays showed that IL4I1 was significantly expressed in TAMs. Importantly, co-culture models proved that IL4I1 significantly promoted the invasion and migration of glioma cells, and induced the polarization of M2-like macrophages. Conclusion: IL4I1 could be a promising immunotherapy target for selective modulation of TAMs and stands as a novel macrophage-related prognostic biomarker in glioma.

immunology
Interleukin‐4 induced 1‐mediated resistance to an immune checkpoint inhibitor through suppression of CD8+ T cell infiltration in melanoma

Shiho Hirose,Tetsuo Mashima,Xunmei Yuan,Makiko Yamashita,Shigehisa Kitano,Shinichi Torii,Toshiro Migita,Hiroyuki Seimiya

DOI: https://doi.org/10.1111/cas.16073

IF: 5.7

2024-01-24

Cancer Science

Abstract:Interleukin‐4 induced 1 overexpression upregulates immunosuppressive gene expression, decreases CD8+ T cell infiltration, and causes resistance to the anti‐ programmed death‐ligand‐1 Ab therapy in a mouse melanoma model. Cancer cells adopt multiple strategies to escape tumor surveillance by the host immune system and aberrant amino acid metabolism in the tumor microenvironment suppresses the immune system. Among the amino acid‐metabolizing enzymes is an L‐amino‐acid oxidase called interleukin‐4 induced 1 (IL4I1), which depletes essential amino acids in immune cells and is associated with a poor prognosis in various cancer types. Although IL4I1 is involved in immune metabolism abnormalities, its effect on the therapeutic efficacy of immune checkpoint inhibitors is unknown. In this study, we established murine melanoma cells overexpressing IL4I1 and investigated their effects on the intratumor immune microenvironment and the antitumor efficacy of anti‐programmed death‐ligand 1 (PD‐L1) antibodies (Abs) in a syngeneic mouse model. As a result, we found that IL4I1‐overexpressing B16‐F10‐derived tumors showed resistance to anti‐PD‐L1 Ab therapy. Transcriptome analysis revealed that immunosuppressive genes were globally upregulated in the IL4I1‐overexpressing tumors. Consistently, we showed that IL4I1‐overexpressing tumors exhibited an altered subset of lymphoid cells and particularly significant suppression of cytotoxic T cell infiltration compared to mock‐infected B16‐F10‐derived tumors. After treatment with anti‐PD‐L1 Abs, we also found a more prominent elevation of tumor‐associated macrophage (TAM) marker, CD68, in the IL4I1‐overexpressing tumors than in the mock tumors. Consistently, we confirmed an enhanced TAM infiltration in the IL4I1‐overexpressing tumors and a functional involvement of TAMs in the tumor growth. These observations indicate that IL4I1 reprograms the tumor microenvironment into an immunosuppressive state and thereby confers resistance to anti‐PD‐L1 Abs.

oncology
Targeted Blockade of TGF-β and IL-6/JAK2/STAT3 Pathways Inhibits Lung Cancer Growth Promoted by Bone Marrow-Derived Myofibroblasts

Jindong Shi,Jingjing Feng,Juan Xie,Zhoufang Mei,Tianyun Shi,Shengmei Wang,Yong Du,Gong Yang,Yougen Wu,Xiaojiao Cheng,Shanqun Li,Liming Zhu,Chung S. Yang,Shuiping Tu,Zhijun Jie

DOI: https://doi.org/10.1038/s41598-017-09020-8

IF: 4.6

2017-01-01

Scientific Reports

Abstract:To investigate the role of TGF-β and IL-6 in myofibroblasts (MFs) - lung cancer cell interactions, lung cancer cells (Lewis and CTM-167 cell lines) were stimulated by IL-6, MF-conditioned medium (MF-CM) or MFs, with or without TGF-β signaling inhibitor - SB431542 and/or JAK2/STAT3 inhibitor - JSI-124. MFs were stimulated by TGF-β, cancer cell-CM or cancer cells, with or without SB431542 and JSI-124. Cell proliferation, the levels of cytokines, expression of mRNA and protein were determined. Mice bearing xenograft tumors were intraperitoneally treated with SB431542 or JSI-124 and monitored for up to 45 days. In co-culture systems, MFs secreted high levels of IL-6, while cancer cells produced high levels of TGF-β. Recombinant IL-6 and MF-CM activated STAT3 and upregulated TGF-β in cancer cells. In contrast, cancer cell-CM or TGF-β stimulated MFs to produce IL-6. Blockade of JAK2/STAT3 and TGF-β signaling by specific inhibitors significantly inhibited cell proliferation in vitro and tumor growth in vivo of lung cancer cells. Our study demontrated that the TGF-β and IL-6/JAK2/STAT3 signaling pathways form a positive feedback signaling loop that mediated the interactions between MFs and lung cancer cells. Targeted inhibiton of this signaling loop could be a new approach for lung cancer prevention and therapy.
Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment

I-Ying Kuo,You-En Yang,Pei-Shan Yang,Yu-Jou Tsai,Hong-Tai Tzeng,Hung-Chi Cheng,Wan-Ting Kuo,Wu-Chou Su,Chih-Peng Chang,Yi-Ching Wang

DOI: https://doi.org/10.7150/thno.60040

IF: 11.6

2021-01-01

Theranostics

Abstract:Background: Increased IL-6 level, M2 macrophages and PD-1+CD8+ T cells in tumor microenvironments (TME) have been identified to correlate with resistance to checkpoint blockade immunotherapy, yet the mechanism remains poorly understood. Rab small GTPase-mediated trafficking of cytokines is critical in immuno-modulation. We have previously reported dysregulation of Rab37 in lung cancer cells, whereas the roles of Rab37 in tumor-infiltrating immune cells and cancer immunotherapy are unclear. Methods: The tumor growth of the syngeneic mouse allograft in wild type or Rab37 knockout mice was analyzed. Imaging analyses and vesicle isolation were conducted to determine Rab37-mediated IL-6 secretion. STAT3 binding sites at PD-1 promoter in T cells were identified by chromatin immunoprecipitation assay. Multiplex fluorescence immunohistochemistry was performed to detect the protein level of Rab37, IL-6 and PD-1 and localization of the tumor-infiltrating immune cells in allografts from mice or tumor specimens from lung cancer patients. Results: We revealed that Rab37 regulates the secretion of IL-6 in a GTPase-dependent manner in macrophages to trigger M2 polarization. Macrophage-derived IL-6 promotes STAT3-dependent PD-1 mRNA expression in CD8+ T cells. Clinically, tumors with high stromal Rab37 and IL-6 expression coincide with tumor infiltrating M2-macrophages and PD1+CD8+ T cells that predicts poor prognosis in lung cancer patients. In addition, lung cancer patients with an increase in plasma IL-6 level are found to be associated with immunotherapeutic resistance. Importantly, combined blockade of IL-6 and CTLA-4 improves survival of tumor-bearing mice by reducing infiltration of PD1+CD8+ T cells and M2 macrophages in TME. Conclusions: Rab37/IL-6 trafficking pathway links with IL-6/STAT3/PD-1 transcription regulation to foster an immunosuppressive TME and combined IL-6/CTLA-4 blockade therapy exerts potent anti-tumor efficacy.

medicine, research & experimental
Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity

Aiqin Gao,Xia Liu,Wenli Lin,Jingnan Wang,Shuyun Wang,Fusheng Si,Lan Huang,Yangjing Zhao,Yuping Sun,Guangyong Peng

DOI: https://doi.org/10.1136/jitc-2020-001536

IF: 12.469

2021-03-01

Journal for ImmunoTherapy of Cancer

Abstract:Background Current immunotherapies including checkpoint blockade therapy have limited success rates in certain types of cancers. Identification of alternative checkpoint molecules for the development of effective strategies for tumor immunotherapy is urgently needed. Immunoglobulin-like transcript 4 (ILT4) is an immunosuppressive molecule expressed in both myeloid innate cells and malignant tumor cells. However, the role of tumor-derived ILT4 in regulating cancer biology and tumor immunity remains unclear. Methods ILT4 expression in tumor cells and patient samples was determined by real-time PCR, flow cytometry, and immunohistochemistry. T cell senescence induced by tumor was evaluated using multiple markers and assays. Moreover, metabolic enzyme and signaling molecule expression and lipid droplets in tumor cells were determined using real-time PCR, western blot and oil red O staining, respectively. Loss-of-function and gain-of-function strategies were used to identify the causative role of ILT4 in tumor-induced T cell senescence. In addition, breast cancer and melanoma mouse tumor models were performed to demonstrate the role of ILT4 as a checkpoint molecule for tumor immunotherapy. Results We reported that ILT4 is highly expressed in human tumor cells and tissues, which is negatively associated with clinical outcomes. Furthermore, tumor-derived ILT4/PIR-B (ILT4 ortholog in mouse) is directly involved in induction of cell senescence in naïve/effector T cells mediated by tumor cells in vitro and in vivo. Mechanistically, ILT4/PIR-B increases fatty acid synthesis and lipid accumulation in tumor cells via activation of MAPK ERK1/2 signaling, resulting in promotion of tumor growth and progression, and induction of effector T cell senescence. In addition, blocking tumor-derived PIR-B can reprogram tumor metabolism, prevent senescence development in tumor-specific T cells, and enhance antitumor immunity in both breast cancer and melanoma mouse models. Conclusions These studies identify a novel mechanism responsible for ILT4-mediated immune suppression in the tumor microenvironment, and prove a novel concept of ILT4 as a critical checkpoint molecule for tumor immunotherapy.

oncology,immunology
IL-3-driven T cell-basophil crosstalk enhances anti-tumor immunity

Jian Wei,Colleen L. Mayberry,Xiaoting Lv,Fangyan Hu,John D. Sears,Taushif Khan,Natalie A. Logan,John J. Wilson,Damien Chaussabel,Chih-Hao Chang

DOI: https://doi.org/10.1101/2024.02.01.578302

2024-02-02

Abstract:Cytotoxic T lymphocytes (CTLs) are pivotal in combating cancer, yet their efficacy is often hindered by the immunosuppressive tumor microenvironment, resulting in exhaustion. This study investigates the role of interleukin (IL)-3 in orchestrating anti-tumor immunity through CTL modulation. Intratumoral CTLs undergo a progressive decline in IL-3 production, which is correlated with impaired cytotoxic function. Augmenting IL-3, through intraperitoneal administration, IL-3-expressing melanoma cells, or IL-3-engineered CD8 T cells, confers protection against tumor progression, concomitant with increased CTL activity. CTLs are critical in this therapeutic efficacy as IL-3 demonstrates no impact on tumor growth in RAG1 knockout mice or following CD8 T cell-depletion. Rather than acting directly, CTL-derived IL-3 exerts its influence on basophils, synergistically amplifying anti-tumor immunity within CTLs. Introducing IL-3-activated basophils retards tumor progression, whereas basophil depletion diminishes the effectiveness of IL-3 supplementation. Furthermore, IL-3 prompts basophils to produce IL-4, which subsequently elevates IFN-γ production and viability of CTLs. Notably, the importance of basophil-derived IL-4 is evident from the absent benefits in IL-3-supplementated, IL-4 knockout tumor-bearing mice. Overall, this research unveils IL-3-mediated CTL-basophil crosstalk in regulating anti-tumor immunity and offers the prospect of harnessing IL-3 sustenance as a promising approach for optimizing and enhancing cancer immunotherapy.

Immunology
Biological Effects of IL-21 on Immune Cells and Its Potential for Cancer Treatment

Meichen Ma,Yuanyuan Xie,Jianhua Liu,Longfei Wu,Yong Liu,Xiaosong Qin

DOI: https://doi.org/10.1016/j.intimp.2023.111154

IF: 5.714

2024-01-01

International Immunopharmacology

Abstract:Interleukin-21 (IL-21), a member of the IL-2 cytokine family, is one of the most important effector and messenger molecules in the immune system. Produced by various immune cells, IL-21 has pleiotropic effects on innate and adaptive immune responses via regulation of natural killer, T, and B cells. An anti-tumor role of IL-21 has also been reported in the literature, as it may support cell proliferation or on the contrary induce growth arrest or apoptosis of the tumor cell. Anti-tumor effect of IL-21 enhances when combined with other agents that target tumor cells, immune regulatory circuits, or other immune-enhancing molecules. Therefore, understanding the biology of IL-21 in the tumor microenvironment (TME) and reducing its systemic toxic and side effects is crucial to ensure the maximum benefits of anti-tumor treatment strategies. In this review, we provide a comprehensive overview on the biological functions, roles in tumors, and the recent advances in preclinical and clinical research of IL-21 in tumor immunotherapy.
ILT2 and ILT4 drive myeloid suppression via both overlapping and distinct mechanisms

Jane Tian,Amir M Ashique,Sabrina Weeks,Tian Lan,Hong Yang,Hung-I H Chen,Christina Song,Kikuye Koyano,Kalyani Mondal,Daniel Tsai,Isla Cheung,Mehrdad Moshrefi,Avantika Kekatpure,Bin Fan,Betty Li,Samir Qurashi,Lauren Rocha,Jonathan Aguayo,Col Rodgers,Marchelle Meza,Darren Heeke,Sara M Medfisch,Chun Chu,Shelley Starck,Nandini Pal Basak,Satish Sankaran,Mohit Malhotra,Suzanne Crawley,Thomas-Toan Tran,Dana Y Duey,Carmence Ho,Igor Mikaelian,Wenhui Liu,Lee B Rivera,Jiawei Huang,Kevin J Paavola,Kyle O'Hollaren,Lisa K Blum,Vicky Y Lin,Peirong Chen,Anjushree Iyer,Sisi He,Julie M Roda,Yan Wang,James Sissons,Alan K Kutach,Daniel D Kaplan,Geoffrey W Stone,Amir M. Ashique,Hung-I H. Chen,Sara M. Medfisch,Nandini Pal. Basak,Dana Y. Duey,Lee B. Rivera,Kevin J. Paavola,Lisa K. Blum,Vicky Y. Lin,Julie M. Roda,Alan K. Kutach,Daniel D. Kaplan,Geoffrey W. Stone

DOI: https://doi.org/10.1158/2326-6066.cir-23-0568

IF: 10.1

2024-02-24

Cancer Immunology Research

Abstract:Solid tumors are dense three-dimensional (3D) multi-cellular structures that enable efficient receptor–ligand trans interactions via close cell–cell contact. Immunoglobulin-like transcript (ILT)2 and ILT4 are related immune suppressive receptors that play a role in the inhibition of myeloid cells within the tumor microenvironment. The relative contributions of ILT2 and ILT4 to immune inhibition in the context of solid tumor tissue has not been fully explored. We present evidence that both ILT2 and ILT4 contribute to myeloid inhibition. We found that while ILT2 inhibits myeloid cell activation in the context of trans-engagement by MHC-I, ILT4 efficiently inhibits myeloid cells in the presence of either cis- or trans-engagement. In a 3D spheroid tumor model, dual ILT2/ILT4 blockade was required for optimal activation of myeloid cells, including the secretion of CXCL9 and CCL5, upregulation of CD86 on dendritic cells, and downregulation of CD163 on macrophages. Humanized mouse tumor models showed increased immune activation and cytolytic T cell activity with combined ILT2 and ILT4 blockade, including evidence of the generation of immune niches, which have been shown to correlate with clinical response to immune checkpoint blockade. In a human tumor explant histoculture system, dual ILT2/ILT4 blockade increased CXCL9 secretion, downregulated CD163 expression, and increased the expression of M1 macrophage, IFN-γ, and cytolytic T cell gene signatures. Thus, we have revealed distinct contributions of ILT2 and ILT4 to myeloid cell biology and provide proof-of-concept data supporting the combined blockade of ILT2 and ILT4 to therapeutically induce optimal myeloid cell reprogramming in the tumor microenvironment.

oncology,immunology
4-1BB: A promising target for cancer immunotherapy

Alyssa Min Jung Kim,Macy Rose Nemeth,Seung-Oe Lim

DOI: https://doi.org/10.3389/fonc.2022.968360

2022-09-14

Abstract:Immunotherapy, powered by its relative efficacy and safety, has become a prominent therapeutic strategy utilized in the treatment of a wide range of diseases, including cancer. Within this class of therapeutics, there is a variety of drug types such as immune checkpoint blockade therapies, vaccines, and T cell transfer therapies that serve the purpose of harnessing the body's immune system to combat disease. Of these different types, immune checkpoint blockades that target coinhibitory receptors, which dampen the body's immune response, have been widely studied and established in clinic. In contrast, however, there remains room for the development and improvement of therapeutics that target costimulatory receptors and enhance the immune response against tumors, one of which being the 4-1BB (CD137/ILA/TNFRSF9) receptor. 4-1BB has been garnering attention as a promising therapeutic target in the setting of cancer, amongst other diseases, due to its broad expression profile and ability to stimulate various signaling pathways involved in the generation of a potent immune response. Since its discovery and demonstration of potential as a clinical target, major progress has been made in the knowledge of 4-1BB and the development of clinical therapeutics that target it. Thus, we seek to summarize and provide a comprehensive update and outlook on those advancements in the context of cancer and immunotherapy.
The Mechanism of Action of IL-2 in the Tumor Microenvironment and Its Application in Melanoma

Jiayi Chen

DOI: https://doi.org/10.54097/fr761521

2024-01-01

Abstract:Cancer, the leading cause of death worldwide, causes a large number of deaths each year and this number is expected to increase with the aging of the population. In this context, it has become particularly important to study and understand in depth the role of cytokines in the tumor microenvironment (TME). Cytokines, particularly interleukin 2 (IL-2), are key regulators of the human immune system and play a pivotal role in the TME.IL-2 plays a crucial role in regulating immune cell proliferation, differentiation, and function, thereby influencing the body's immune response to tumors. However, signaling by IL-2 and its receptor (IL-2R) may be dysregulated in TME, and this dysregulation has profound effects on tumor growth and anti-tumor immune responses. Specifically, dysregulated IL-2 signaling may promote tumor growth and spread while suppressing the body's immune response to the tumor. Translated with DeepL.com (free version) This review summarizes the mechanism of IL-2 and its signal pathway in the TME according to the current popular clinical research object. Based on the side effects of IL-2 during clinical application (such as short half-life and toxicity of high doses of IL-2), this article introduces a new strategy for developing IL-2-cytokine immunotherapy in melanoma treatment. Together, this work aims to provide readers with a timely view of the field of engineered IL-2, highlighting a more promising avenue for future research and development.
Interleukin-1 (IL-1) and the inflammasome in cancer

Vincent Pretre,Dimitrios Papadopoulos,Jean Regard,Marc Pelletier,Janghee Woo

DOI: https://doi.org/10.1016/j.cyto.2022.155850

IF: 3.926

2022-05-01

Cytokine

Abstract:Numerous preclinical and clinical studies have demonstrated the significant contribution of inflammation to the development and progression of various types of cancer. Inflammation in the tumor microenvironment mediates complex interactions between innate immunity, adaptive immunity, microbiomes and stroma, and ultimately alters the overall fitness of tumor cells at multiple stages of carcinogenesis. Malignancies are known to arise in areas of chronic inflammation and inflammation in the tumor microenvironment (often called tumor-promoting inflammation) is believed to allow cancer cells to evade immunosurveillance while promoting genetic instability, survival and progression. Among the strongest data suggesting a causal role for inflammation in cancer come from the recent CANTOS trial which demonstrated that interleukin-1β (IL-1β) inhibition with canakinumab leads to a significant, dose-dependent decrease in incident lung cancer. This observation has launched a series of additional clinical studies to understand the role of IL-1β and the inflammasome in cancer, and the clinical utility of IL-1β inhibition in different stages of lung cancer. In this article we will review recent data implicating IL-1β signaling and its upstream regulator NLRP3 in both solid tumor and hematologic malignancies. We will discuss the key preclinical observations and the current clinical landscape, and describe the pharmacologic tools which will be used to evaluate the effects of blocking tumor-promoting inflammation clinically.

biochemistry & molecular biology,immunology,cell biology
The two faces of IL-6 in the tumor microenvironment

Daniel T. Fisher,Michelle M. Appenheimer,Sharon S. Evans

DOI: https://doi.org/10.1016/j.smim.2014.01.008

IF: 10.671

2014-02-01

Seminars in Immunology

Abstract:Within the tumor microenvironment, IL-6 signaling is generally considered a malevolent player, assuming a dark visage that promotes tumor progression. Chronic IL-6 signaling is linked to tumorigenesis in numerous mouse models as well as in human disease. IL-6 acts intrinsically on tumor cells through numerous downstream mediators to support cancer cell proliferation, survival, and metastatic dissemination. Moreover, IL-6 can act extrinsically on other cells within the complex tumor microenvironment to sustain a pro-tumor milieu by supporting angiogenesis and tumor evasion of immune surveillance. A lesser known role for IL-6 signaling has recently emerged in which it plays a beneficial role, presenting a fairer face that opposes tumor growth by mobilizing anti-tumor T cell immune responses to attain tumor control. Accumulating evidence establishes IL-6 as a key player in the activation, proliferation and survival of lymphocytes during active immune responses. IL-6 signaling can also resculpt the T cell immune response, shifting it from a suppressive to a responsive state that can effectively act against tumors. Finally, IL-6 plays an indispensable role in boosting T cell trafficking to lymph nodes and to tumor sites, where they have the opportunity to become activated and execute their cytotoxic effector functions, respectively. Here, we discuss the dual faces of IL-6 signaling in the tumor microenvironment; the dark face that drives malignancy, and the fairer aspect that promotes anti-tumor adaptive immunity.

immunology

IL-4 within the bone marrow: a key driver of lung tumorigenesis

Endogenously Expressed IL-4Rα Promotes the Malignant Phenotype of Human Pancreatic Cancer in Vitro and in Vivo

IL4I1: a novel molecular biomarker represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer

IL-20RB Mediates Tumoral Response to Osteoclastic Niches and Promotes Bone Metastasis of Lung Cancer

IL-4 promotes immunotherapy resistance

Innate lymphoid-macrophage crosstalk promotes lung cancer regression in response to IL-12 therapy

IL-4 Downregulates PD-L1 Level Via SOCS1 Upregulation-Induced JNK Deactivation to Enhance Antitumor Immunity in In Vitro Colorectal Cancer

IL4I1 enhances PD-L1 expression through JAK/STAT signaling pathway in lung adenocarcinoma

Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies

IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy

Interleukin‐4 induced 1‐mediated resistance to an immune checkpoint inhibitor through suppression of CD8+ T cell infiltration in melanoma

Targeted Blockade of TGF-β and IL-6/JAK2/STAT3 Pathways Inhibits Lung Cancer Growth Promoted by Bone Marrow-Derived Myofibroblasts

Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment

Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity

IL-3-driven T cell-basophil crosstalk enhances anti-tumor immunity

Biological Effects of IL-21 on Immune Cells and Its Potential for Cancer Treatment

ILT2 and ILT4 drive myeloid suppression via both overlapping and distinct mechanisms

4-1BB: A promising target for cancer immunotherapy

The Mechanism of Action of IL-2 in the Tumor Microenvironment and Its Application in Melanoma

Interleukin-1 (IL-1) and the inflammasome in cancer

The two faces of IL-6 in the tumor microenvironment